Prevalence of the Metabolic Syndrome Among Obese Adolescents Enrolled in a Multidisciplinary Weight Management Program: Clinical Correlates and Response to Treatment
Restricted accessResearch articleFirst published online June, 2009
Prevalence of the Metabolic Syndrome Among Obese Adolescents Enrolled in a Multidisciplinary Weight Management Program: Clinical Correlates and Response to Treatment
The aim of this study was to determine the prevalence of the metabolic syndrome at baseline and after 6 months of lifestyle modification among obese adolescents referred to a multidisciplinary weight management program.
Methods:
A total of 165 obese adolescents were evaluated at baseline, and measurements were repeated in 57 subjects who completed 6 months of the program. Metabolic syndrome was defined as having three or more of the following: a body mass index (BMI) >97th percentile, hypertension, low high-density lipoprotein cholesterol (HDL-C), hypertriglyceridemia, and impaired fasting glucose (IFG).
Results:
The prevalence of a BMI >97th percentile, hypertension, hypertriglyceridemia, low HDL-C, and IFG was 92.7, 54.5, 29.1, 26.7, and 2.4%, respectively. The prevalence of the metabolic syndrome at baseline was 30.3%. After 6 months of lifestyle modification, BMI z scores, percent body fat, total cholesterol, and low-density lipoprotein cholesterol (LDL-C) decreased significantly from baseline; however, there was no significant change in the number of subjects demonstrating ≥three criteria of the metabolic syndrome.
Conclusions:
Approximately one third of the study subjects met the criteria of the metabolic syndrome, emphasizing the growing concern for the future development of premature cardiovascular disease in this high-risk population. Our data suggest that new strategies for lifestyle modification may be needed to improve cardiovascular risk factors significantly among adolescents with obesity.
BarlowSE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics, 2007; 120,Suppl 4:S164–192.
3.
OgdenCL, CarrollMD, CurtinLR, McDowellMA, TabakCJ, FlegalKM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA, 2006; 295:1549–1555.
4.
WeissR, DziuraJ, BurgertTS, TamborlaneWV, TaksaliSE, YeckelCW, AllenK, LopesM, SavoyeM, MorrisonJ, SherwinRS, CaprioS. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med, 2004; 350:2362–2374.
5.
MorrisonJA, FriedmanLA, Gray-McGuireC. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics, 2007; 120:340–345.
6.
KuczamarskiRJ, OgdenCL, GuoSS, Grummer-StrawnLM, FlegalKM. 2000 CDC Growth Charts for the United States: Methods and Development 246, 1–190. Hyattsville MD: National Center for Health Statistics Vital Series and Health Statistics Series 11, 2002.
7.
MatthewsDR, HoskerJP, RudenskiAS, NaylorBA, TreacherDF, TurnerRC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28412–28419.
8.
FriedewaldWT, LevyRI, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18:499–502.
9.
KeskinM, KurtogluS, KendirciM, AtabekME, YaziciC. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics, 2005; 115:e500–e503.
10.
Standards of medical care in diabetes—2008. Diabetes Care, 2008; 31,Suppl 1:S12–S54.
11.
MatsudaM, DeFronzoRA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care, 1999; 22:1462–1470.
12.
The fourth report on the diagnosis, evaluation, treatment of high blood pressure in children, adolescents. Pediatrics, 2004; 114,2 Suppl 4th Report:555–576.
13.
LorenzoC, OkoloiseM, WilliamsK, SternMP, HaffnerSM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care, 2003; 26:3153–3159.
14.
IsomaaB, AlmgrenP, TuomiT, ForsenB, LahtiK, NissenM, TaskinenMR, GroopL. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001; 24:683–689.
15.
LakkaHM, LaaksonenDE, LakkaTA, NiskanenLK, KumpusaloE, TuomilehtoJ, SalonenJT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 2002; 288:2709–2716.
16.
BitsoriM, KafatosA. Dysmetabolic syndrome in childhood and adolescence. Acta Paediatr, 2005; 94:995–1005.
17.
LeeS, BachaF, GungorN, ArslanianS. Comparison of different definitions of pediatric metabolic syndrome: relation to abdominal adiposity, insulin resistance, adiponectin, and inflammatory biomarkers. J Pediatr, 2008; 152:177–184.
18.
CookS, AuingerP, LiC, FordES. Metabolic syndrome rates in United States adolescents, from the National Health and Nutrition Examination Survey, 1999–2002. J Pediatr, 2008; 152:165–170.
19.
GolleyRK, MagareyAM, SteinbeckKS, BaurLA, DanielsLA. Comparison of metabolic syndrome prevalence using six different definitions in overweight pre-pubertal children enrolled in a weight management study. Int J Obes (Lond), 2006; 30:853–860.
20.
JessupA, HarrellJS. The metabolic syndrome: look for it in children and adolescents, too!Clin Diabetes, 2005; 23:26–32.
21.
GoodmanE. Pediatric metabolic syndrome: smoke and mirrors or true magic?J Pediatr, 2006; 148:149–151.
22.
CookS, WeitzmanM, AuingerP, NguyenM, DietzWH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med, 2003; 157:821–827.
23.
de FerrantiSD, GauvreauK, LudwigDS, NeufeldEJ, NewburgerJW, RifaiN. Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey Circulation. Circulation, 2004; 110:2494–2497.
24.
FordES, AjaniUA, MokdadAH. The metabolic syndrome and concentrations of C-reactive protein among US youth. Diabetes Care, 2005; 28:878–881.
25.
American Academy of Pediatrics National Cholesterol Education Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics, 1992; 89,3 Pt 2:525–584.
26.
GrundySM, BrewerHBJr, CleemanJI, SmithSCJr, LenfantC. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 2004; 109:433–438.
27.
QuintosJB, MuzumdarH, GeorgeM, MercadoAB, LuH, SternbergA, RaoM, CastellsS. The prevalence of metabolic syndrome in inner city obese African-American youth. Pediatr Endocrinol Rev, 2006; 3,Suppl 4:571–575.
28.
KranzS, MahoodLJ, WagstaffDA. Diagnostic criteria patterns of US children with Metabolic Syndrome: NHANES 1999–2002. Nutr J, 2007; 6:38.
29.
CruzML, WeigensbergMJ, HuangTT, BallG, ShaibiGQ, GoranMI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab, 2004; 89:108–113.
30.
InvittiC, MaffeisC, GilardiniL, PontiggiaB, MazzilliG, GirolaA, SartorioA, MorabitoF, VibertiGC. Metabolic syndrome in obese Caucasian children: prevalence using WHO-derived criteria and association with nontraditional cardiovascular risk factors. Int J Obes (Lond), 2006; 30:627–633.
31.
Rodriguez-MoranM, Salazar-VazquezB, ViolanteR, Guerrero-RomeroF. Metabolic syndrome among children and adolescents aged 10–18 years. Diabetes Care, 2004; 27:2516–2517.
32.
MonzaviR, DreimaneD, GeffnerME, BraunS, ConradB, KlierM, KaufmanFR. Improvement in risk factors for metabolic syndrome and insulin resistance in overweight youth who are treated with lifestyle intervention. Pediatrics, 2006; 117:e1111–e1118.
33.
WilliamsCL, HaymanLL, DanielsSR, RobinsonTN, SteinbergerJ, ParidonS, BazzarreT. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 2002; 106:143–160.
34.
SprangerJ, KrokeA, MohligM, BergmannMM, RistowM, BoeingH, PfeifferAF. Adiponectin and protection against type 2 diabetes mellitus. Lancet, 2003; 361:226–228.
35.
OuchiN, KiharaS, AritaY, NishidaM, MatsuyamaA, OkamotoY, IshigamiM, KuriyamaH, KishidaK, NishizawaH, HottaK, MuraguchiM, OhmotoY, YamashitaS, FunahashiT, MatsuzawaY. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 2001; 103:1057–1063.
36.
YokotaT, OritaniK, TakahashiI, IshikawaJ, MatsuyamaA, OuchiN, KiharaS, FunahashiT, TennerAJ, TomiyamaY, MatsuzawaY. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000; 96:1723–1732.
37.
HardenKA, CowanPA, Velasquez-MieyerP, PattonSB. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. J Am Acad Nurse Pract, 2007; 19:368–377.
38.
CarantiDA, de MelloMT, PradoWL, TockL, SiqueiraKO, de PianoA, LofranoMC, CristofaloDM, LedermanH, TufikS, DamasoAR. Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents. Metabolism, 2007; 56:1293–1300.
39.
ChenAK, RobertsCK, BarnardRJ. Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children. Metabolism, 2006; 55:871–878.
40.
ZellerM, KirkS, ClaytorR, KhouryP, GriemeJ, SantangeloM, DanielsS. Predictors of attrition from a pediatric weight management program. J Pediatr, 2004; 144:466–470.
41.
CarantiDA, de MelloMT, PradoWL, TockL, SiqueiraKO, de PianoA, LofranoMC, CristofaloDM, LedermanH, TufikS, DamasoAR. Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents. Metabolism, 2007; 56:1293–1300.
